Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression re...

Descripción completa

Detalles Bibliográficos
Autores principales: Fingrut, Warren, Davis, Wendy, McGinnis, Eric, Dallas, Karen, Ramadan, Khaled, Merkeley, Hayley, Leitch, Heather, Abou Mourad, Yasser, Cassaday, Ryan D., Ross, Camilla, Léger, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900888/
https://www.ncbi.nlm.nih.gov/pubmed/33704192
http://dx.doi.org/10.3390/curroncol28010027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900888/
https://www.ncbi.nlm.nih.gov/pubmed/33704192
http://dx.doi.org/10.3390/curroncol28010027

Ejemplares similares